A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Exclusion criteria

• ✕. History of craniocerebral trauma, conscious disturbance, epilepsy,cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;
• ✕. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythm ia in the past;
• ✕. Pregnant (or lactating) women;
• ✕. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
• ✕. Active infection of hepatitis B virus or hepatitis C virus;
• ✕. Systemic steroids have used in the 4 weeks before participating in the treatment (except recently or currently using inhaled steroids);
• ✕. Those who have used any gene therapy products before.
• ✕. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;